市場調查報告書
商品編碼
1260686
電生理學市場——按產品、按適應症、最終用途和全球預測,2023-2032 年Electrophysiology Market - By Product, By Indication, By End-use & Global Forecast, 2023 - 2032 |
電生理學行業預計到 2032 年將實現巨大增長。
由於與生活方式相關的健康狀況普遍存在,電生理學 (EP) 測試廣受歡迎。 久坐不動的生活方式、過量飲酒和吸煙大大增加了心髒病的發病率。
此外,人口老齡化也是加重醫療負擔的重要因素。 心力衰竭、心動過緩期間的心臟起搏、房顫和心肌梗死後的室性心律失常是需要心臟 EP 的一些健康狀況。
在過去十年中,醫療保健領域的消融技術取得了重大進展,人們越來越努力設計針對心律失常的自動化單次注射治療。 先進的 3D 繪圖技術的發展以及人工智能和機器學習的使用將使心髒病的有效診斷和治療成為可能。
2022 年 7 月,Stereotaxis 為其磁性介入消融導管“MAGiC”導管申請了 CE 標誌,該導管旨在藉助機器人導航支持微創手術。 GE Healthcare、Japan Lifeline、Medtronic、Siemens AG 和 Abbott Laboratories 等其他參與者正在引領機器人心臟消融手術的類似創新。
電生理學市場分為產品、適應症、最終用途和區域。
按產品劃分,我們分為電生理診斷導管、電生理消融導管和電生理實驗室設備。 到 2022 年,EP 消融導管部分的收入份額將超過 26 億美元。 由於新興國家人口老齡化,越來越多的慢性病患者預計將推動對 EP 消融導管的需求。
根據跡象,到 2032 年底,房撲電生理學市場份額預計將超過 17 億美元。 心房撲動是由高血壓等健康狀況引起的心臟電系統變化引起的疾病。 根據世界衛生組織 (WHO) 的數據,在過去 30 年中,30-79 歲人群的高血壓病例從 6.5 億增加到 12.8 億。
電生理學市場根據最終用途細分為醫院、門診手術中心、導管插入術/EP 實驗室等。 到 2022 年,門診手術中心部門的收入份額將超過 1.8 億美元。 由於方便使用先進的醫療設施,患者越來越喜歡在門診進行單日心血管手術。 我們的門診手術中心還以實惠的價格提供一流的醫療保健服務。
到 2032 年底,亞太地區的電生理學市場預計將超過 39 億美元。 增加公共和私人資金以支持心血管疾病意識將補充亞太地區的行業擴張。 中國和印度等亞太國家的醫療旅遊正在快速增長,預計在預測期內將提供有利可圖的商業前景。
The electrophysiology industry is anticipated to record tremendous growth by 2032. Electrophysiology (EP) tests have gained significant popularity due to the high prevalence of lifestyle-related health conditions. Due to sedentary lifestyles, excessive alcohol consumption, and tobacco smoking, the incidences of heart disease have increased considerably.
Furthermore, aging is a crucial factor in increasing the healthcare burden. Heart failure, cardiac pacing in case of bradycardia, atrial fibrillation, and ventricular arrhythmias post-myocardial infarction are some of the health conditions that require cardiac EP.
Over the last decade, the healthcare sector has witnessed substantial advancements in ablation technology, with increasing efforts to design automated, single-shot treatments for cardiac arrhythmias. The development of sophisticated 3D mapping techniques and the use of AI and machine learning will enable efficient diagnosis and treatment of cardiac diseases.
In July 2022, Stereotaxis applied for CE Marking of its MAGiC catheter, a magnetic interventional ablation catheter designed to support minimally invasive surgeries with the help of robotic navigation. Similar innovations in robotics-based cardiac ablation procedures are being led by other players such as GE Healthcare, Japan Lifeline, Medtronic, Siemens AG, and Abbott Laboratories among others.
The electrophysiology market is classified into product, indication, end-use, and region.
Based on product, the industry is bifurcated into EP diagnostic catheters, EP ablation catheters, and EP laboratory devices. The EP ablation catheters segment accounted for more than USD 2.6 billion in revenue share in 2022. The increasing geriatric population in developing countries contributing to a large patient pool of chronic diseases will propel the demand for EP ablation catheters.
By indication, the electrophysiology market share from atrial flutter is projected to reach over USD 1.7 billion by the end of 2032. Atrial flutter is a condition that occurs due to changes in the electrical system of the heart, caused by health conditions such as hypertension. According to the World Health Organization (WHO), cases of hypertension among individuals aged 30-79 years increased from 650 million to 1.28 billion over the last three decades.
With respect to end-use, the electrophysiology market is segregated into hospitals, ambulatory surgery centers, catheterization/EP laboratories, and others. The ambulatory surgery centers segment accounted for a revenue share of more than USD 180 million in 2022. Due to accessibility to advanced medical facilities, patients increasingly prefer ambulatory units for single-day cardiovascular surgeries. Ambulatory surgery centers also provide best-in-class healthcare at an affordable rate.
Asia Pacific electrophysiology market is poised to exceed USD 3.9 billion by the end of 2032. Increasing public and private funding encouraging awareness initiatives pertaining to cardiovascular diseases will complement industry expansion across APAC. Rapidly pacing medical tourism across APAC countries such as China, and India will offer lucrative business prospects over the projected timeframe.